

























































One step closer to finding the Fountain of Youth
in our muscles: can we grow old while staying
young at heart?
Sveva Bollini*
Department of Experimental Medicine (DIMES), University of Genova, Via A. Pastore 3, 16132 Genova, Italy
Commentary on ‘Aging disrupts muscle stem cell function by
impairing matricellular WISP1 secretion from fibro-adipogenic
progenitors’ by L. Lukjanenko et al., Cell Stem cell, 2019.1
Senectus ipsa morbus est [Publius Terentius Afer: Phormio: a. IV, (160 B.C.)]:
ageing is itself a disease. The quest of eternal youth has always been a ma-
jor dream for humanity, from mythology up to current science. People
worldwide are living longer with the population over 60 years old raising
up to 2 billion by 2050.2 Thus, the pursuit for a molecular ‘holy grail’ for
ageing, if not healthy, at least smarter, is a medical demand.
The decline of working potential and regenerative properties is main
hallmarks of tissue aging. The skeletal muscle healing restorative capacity
relies on activation of resident progenitors, the muscle stem cells (MuSCs),
which become less responsive and dysregulated as getting elderly.3
Recently, Lukjanenko et al.1 elegantly addressed ageing detrimental influ-
ence on MuSCs in mice. Authors focused on the functional paracrine
cross-talk between MuSCs and their regulatory cells in the skeletal muscle
niche, namely fibro-adipogenic precursors (FAPs). Ageing significantly
affects FAPs, as they fail to support MuSC renewal and differentiation and
increase their pro-fibrotic commitment after muscle injury. On the con-
trary, young FAPs modulate the muscle healing system by stronger para-
crine effects on MuSCs. Authors pin-pointed a molecular candidate in
WISP1 (Wnt1 Inducible Signalling pathway Protein 1) within the secre-
tome (i.e. the whole of cell-secreted paracrine molecules) of the injury-
activated and young FAPs, as further validated in WISP-/- mice with age-
related defects in muscle regeneration; paracrine therapy via systemic ad-
ministration of recombinant WISP1 in aged mice showed to restore regen-
erative MuSC myogenesis. Therefore, targeting the signalling cross-talk
within the MuSC niche via the FAP secretome, could help rejuvenating
muscle healing, while counteracting age-related decay of regenerative po-
tential.
This study provides relevant insights for cardiac repair and regeneration
as well. Ageing is a leading factor for cardiovascular disease, with the heart
long being considered devoid of any regenerative capacity. Disease- or
injury-related compensatory mechanisms include hypertrophy of resident
cardiomyocytes and organ-wide remodelling, leading to heart failure. In
the last years, growing interest has been dedicated to the identification of
endogenous myocardial precursors with responsive restorative potential.
Several populations of cardiac progenitor cells (CPCs) have been de-
scribed with putative cardiovascular differentiation capacity; despite initial
enthusiasm, an increasing body of works has been questioning the efficacy
of CPC myogenic potential following injury. Indeed, in the adult injured
heart, CPCs have shown to preferentially commit to a fibroblastic or vas-
cular phenotype, with the few newly generated cardiomyocytes deriving
from surviving pre-existing ones.4 Deutsch et al.5 clearly showed that myo-
cardial infarction triggers resident murine cardiac stromal cells expressing
an activated enhancer for the multipotent progenitor embryonic gene
Nkx2.5. Although these cells retrieve expression of stem cell- and early
cardiac transcription factors, they undertake a pro-fibrotic fate, rather than
differentiating into new cardiomyocytes, suggesting that genetic restoration
of the embryonic programme during adulthood might not be sufficient to
reinstate developmental plasticity. Yet, CPCs have demonstrated to in-
struct the cardiac microenvironment by modulatory signalling and support
local angiogenesis after injury6; ex vivo administration of the CPC secre-
tome (including extracellular vesicles) in rodent models of myocardial in-
farction results in cardiac function improvement with preservation of
viable cardiomyocytes.7 Hence, CPCs are likely to be considered endoge-
nous regulatory supporting cells, rather than myogenic precursors; they
are primed by a fibrogenic signature and endowed with relevant secretory
potential, thus resembling the cardiac counterpart to skeletal muscle FAPs.
Mammal cardiomyocytes become post-mitotic during the complete
maturation from peri-natal age into adulthood, with meagre turnover po-
tential during life. In contrast, the early neonatal mouse myocardium main-
tains efficient regeneration potential after extensive damage via de-
differentiation and proliferation of pre-existing cardiomyocytes; however,
this restorative response is strictly limited to the first 7 days after birth,
with clear transition to fibrosis/scarring soon afterwards.8 The prompt
peri-natal cardiomyocyte withdrawal from cell cycle into the differentiated
resting state implies a drastic ‘memory loss’ of endogenous regenerative
mechanisms, as cells ‘age’ into the mature functional phenotype. Emerging
data have indicated some putative candidate targets to retrieve and ‘reju-
venate’ resident cardiomyocyte proliferative potential, such as the activa-
tion of cell cycle regulators or the inhibition of GSK-3 kinase signalling, a
sensitive regulator of mammalian myocardial renewal.9
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.Notably, during cardiogenesis epicardial CPC provide paracrine signal-
ling to the developing myocardium by means of mitogens influencing car-
diomyocyte renewal; embryonic epicardial CPC contribute to cardiac
fibroblasts, which support cardiomyocyte expansion; conversely, adult
cardiac fibroblasts drive cardiomyocyte hypertrophy.10 Such close cross-
talk between cardiomyocytes and pro-fibrogenic CPC strongly resem-
bles the paracrine relationship of skeletal muscle FAPs and MuSCs. Since
WISP1 has been shown to play a crucial role in muscle regeneration,
evaluation on its paracrine potential on the CPC-cardiomyocyte axis
might offer valuable understandings for myocardial regeneration. Human
recombinant WISP1 has been described to exert cardioprotective
effects on isolated adult mouse cardiomyocytes experiencing
anthracycline-induced cardiotoxicity, via inhibition of GSK-3b phosphor-
ylation with b-catenin nuclear translocation.11 Pharmacological blocking
of GSK-3 promotes proliferation in human neonatal cardiomyocytes by
up-regulating cell cycle and cytokinesis mechanisms via canonical Wnt
pathway12; thus, it is reasonable to think that WISP1 might also impact
myocardial renewal. In stark contrast, adult rodents infused with
Angiotensin-II show increased WISP1 expression in proliferative cardiac
fibroblasts resulting in myocardial hypertrophy and activation of fibro-
sis.13 By acting as pro-mitogenic and pro-survival paracrine effector by
cardiac cell type-specific manner, WISP1 exerts complex biological
effects, acting as friend or foe. Therefore, it might be interesting to assess
its possible role in rejuvenating adult cardiomyocyte cell cycle progres-
sion when secreted by embryonic/peri-natal CPC compared to adult
ones.
Lukjanenko et al. also demonstrated that skeletal muscle FAPs modu-
late the expression of the PDGFRa gene intronic variant (PDGFRaIn) as
they age; PDGFRaIn prevents FAP skewing to fibrotic cells and it gets
reduced in elderly and failing progenitors. Endogenous CPC have been
described as PDGFRa-positive stromal cells,14 contributing to ventricle
fibrofatty scarring when impaired during arrhythmogenic cardiomyopa-
thy.15 Then, profiling PDGFRaIn modulation during CPC ageing could
offer meaningful information as therapeutic target to limit unnecessary fi-
brosis.
This body of work endorses the relevance of the paracrine modula-
tion of the tissue microenvironment to inhibit functional ageing. Tissue
rejuvenation might be pursued by stimulating endogenous cells via suit-
able paracrine instruction, rather than by coercing their genome by
means of reprogramming or by replacing them through cell transplanta-
tion. Since increasing evidences indicates that restoration of resident car-
diomyocyte proliferation represents the primary therapeutic mechanism
for heart regeneration, results from Lukjanenko et al. might offer useful
insights in the cardiac scenario. Rejuvenation of the CPC secretome
might offer a putative working strategy to unlock resident cardiomyocyte
renewal and provide fertile soil for a good seed. Hence, reinstating the
developmental CPC-cardiomyocyte molecular cross-talk during adult-
hood might help growing old, while staying young at heart.
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